Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MIMEDX GROUP, INC.

Get SEC filing alerts via email and in your feed for MIMEDX GROUP, INC.

MDXG

MIMEDX GROUP, INC.

About MIMEDX GROUP, INC.

MIMEDX Group, Inc. specializes in developing and distributing placental and animal-derived biologic tissues for wound care and surgical applications. Its core products include human placental allografts and xenografts used to treat chronic wounds, burns, and surgical sites. The company leverages proprietary processing methods, extensive scientific evidence, and regulatory compliance to serve healthcare providers globally, focusing on innovation, product diversification, and expanding clinical and international markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MIMEDX GROUP, INC.

1
1
MIMEDX GROUP, INC. MiMedx Group Reports 33.1% Decline in Q1 2026 Net Sales, Net Loss of $10.86 Million

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MIMEDX GROUP, INC. MiMedx Group Reports 20% Revenue Growth to $418.6 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
MIMEDX GROUP, INC. MiMedx Group Reports 35.3% Revenue Growth to $113.7 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MIMEDX GROUP, INC. MiMedx Reports 13.1% Net Sales Increase to $98.6 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MIMEDX GROUP, INC. MiMedx Reports 4.1% Net Sales Increase to $88.2 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MIMEDX GROUP, INC. MiMedx Group Reports 8.5% Sales Increase to $348.9 Million, Net Income Declines by 37.7%

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MIMEDX GROUP, INC. MiMedx Group Reports 2.9% Revenue Growth and Improved Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments